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Summary
Background Worldwide, haemoglobin E β-thalassaemia is the most common genotype of severe β-thalassaemia. The 
paucity of long-term data for this form of thalassaemia makes evidence-based management challenging. We did a 
long-term observational study to define factors associated with survival and complications in patients with 
haemoglobin E thalassaemia.
Methods In this prospective, longitudinal cohort study, we included all patients with haemoglobin E thalassaemia who 
attended the National Thalassaemia Centre in Kurunegala, Sri Lanka, between Jan 1, 1997, and Dec 31, 2001. Patients 
were assessed up to three times a year. Approaches to blood transfusions, splenectomy, and chelation therapy shifted 
during this period. Survival rates between groups were evaluated using Kaplan-Meier survival function estimate curves 
and Cox proportional hazards models were used to identify risk factors for mortality.
Findings 109 patients (54 [50%] male; 55 [50%] female) were recruited and followed up for a median of 18 years 
(IQR 14–20). Median age at recruitment was 13 years (range 8–21). 32 (29%) patients died during follow-up. Median 
survival in all patients was 49 years (95% CI 45–not reached). Median survival was worse among male patients (hazard 
ratio [HR] 2·51, 95% CI 1·16–5·43), patients with a history of serious infections (adjusted HR 8·49, 2·90–24·84), and 
those with higher estimated body iron burdens as estimated by serum ferritin concentration (adjusted HR 1·03, 
1·01–1·06 per 100 units). Splenectomy, while not associated with statistically significant increases in the risks of death or 
serious infections, ultimately did not eliminate a requirement for scheduled transfusions in 42 (58%) of 73 patients. 
Haemoglobin concentration less than or equal to 4·5 g/dL (vs concentration >4·5 g/dL), serum ferritin concentration 
more than 1300 µg/L (vs concentration ≤1300 µg/L), and liver iron concentration more than 5 mg/g dry weight of liver (vs 
concentration ≤5 mg/g) were associated with poorer survival.
Interpretation Patients with haemoglobin E thalassaemia often had complications and shortened survival compared 
with that reported in high-resource countries for thalassaemia major and for thalassaemia intermedia not involving 
an allele for haemoglobin E. Approaches to management in this disorder remain uncertain and prospective studies 
should evaluate if altered transfusion regimens, with improved control of body iron, can improve survival.
Funding Wellcome Trust, Medical Research Council, US March of Dimes, Anthony Cerami and Ann Dunne 
Foundation for World Health, and Hemoglobal.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 
4.0 license.
Introduction 
The major forms of thalassaemia are recognised as a 
severe public health problem throughout Asia, where 
during the past 25 years, improvements in public 
health have resulted in declines in mortality in children, 
including those with serious genetic diseases who 
would, formerly, have died in infancy. As a result, 
there has been increasing recognition of the burden of 
thalassaemia.1 Worldwide, 40 000 new births of children 
with thalassaemia are recorded annually: half in 
South-East Asia, and the rest throughout the Eastern 
Mediterranean region, Europe, and the Americas.2 
Although prevalence remains uneven in the USA, 
severe thalassaemia is now identified in one in 
55 000 newborn babies in the state of California, which 
is home to a large Asian population.3
Worldwide, nearly half of the disease burden of 
thalassaemia is accounted for by haemoglobin E 
thalassaemia, a form of thalassaemia most commonly 
identified throughout Thailand, Cambodia, Indonesia, 
and China.4 Arising from compound heterozygosity for a 
β-thalassaemia allele and the abnormal haemoglobin E, 
haemoglobin E thalassaemia has a complex patho-
physiology, derived from globin chain imbalance, 
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ineffective erythropoiesis, and shortened red blood cell 
survival.5 The clinical course of many patients appears 
indistinguishable from that of severe thalassaemia major 
in which, beginning in infancy, regular transfusions are 
required to prevent anaemia, hepatosplenomegaly, 
extramedullary marrow expansion, and impaired growth 
and develop ment. By contrast, even in the absence 
of regular blood transfusions, many patients with 
haemoglobin E thalassaemia do not have these 
complications6,7 and, even when irregularly transfused, 
have better survival than do patients with thalassaemia 
major.8,9 Because of this broad clinical variability and 
because no long-term studies have reported survival or 
complications in people with haemoglobin E thalassaemia, 
optimal treatment for the disease remains uncertain.
This study was initiated in Sri Lanka, following a 
request from a local paediatrician in one centre in Sri 
Lanka for advice on the management of haemoglobin E 
thalassaemia, which, as we ultimately reported, accounts 
for a third of patients with severe β-thalassaemia in 
the country.10 Subsequently, we documented the clinical 
features, approaches to transfusion, complications, and 
deaths in patients with haemoglobin E thalassaemia, 
in an effort to elucidate the factors associated with 
survival and complications in this under-studied form 
of thalassaemia. To our knowledge, this is the first 
longitudinal analysis of survival, factors affecting 
survival, and complications in patients with haemoglobin 
E thalassaemia, as observed over 20 years in a single 
Asian centre.
Methods 
Study design and participants 
In this prospective, longitudinal cohort study, we included 
all patients with haemoglobin E thalassaemia who 
attended the National Thalassaemia Centre, Kurunegala, 
Sri Lanka, between Jan 1, 1997, and Dec 31, 2001. There 
were no exclusion criteria. No patients were lost to 
follow-up. A Strengthening the Reporting of Observational 
Studies in Epidemiology flowchart is shown in the 
appendix (p 1). Ethical permission for the study was 
obtained from the University of Colombo and the Central 
Oxford Research Ethics Committee (first obtained in 1996 
and extended in 2006, 2013, and 2018). Written informed 
consent was not sought from individual patients because 
no experimental intervention was implemented.
Procedures and outcomes 
Haemoglobin E thalassaemia was confirmed by 
DNA analysis, which also confirmed co-inheritance of 
genetic modifiers (α-thalassaemia; the rs7482144 [Xmn1] 
polymorphism [G→A] 5ʹ to HBG2; and the rs4671393 
Research in context
Evidence before this study
We searched MEDLINE and PubMed databases using the terms 
“haemoglobin E thalassemia” and “haemoglobin E 
thalassaemia” for articles published in English between 
Jan 1, 1960, and Dec 31, 2017. We also reviewed the references 
of all articles identified by this search. We found no long-term 
(>5 years) studies of survival, or the factors influencing survival, 
in people with haemoglobin E thalassaemia.
Added value of this study
Our study provides information about survival, and factors 
influencing survival, in patients with haemoglobin E 
thalassaemia, neither of which were previously reported in the 
literature. We report that survival in patients with haemoglobin 
E thalassaemia is poor compared with that reported in high-
resource countries for thalassaemia major and for thalassaemia 
intermedia not involving an allele for haemoglobin E, 
but superior to that reported in patients with thalassaemia in 
Sri Lanka cared for outside a main treatment centre. 
Our analysis defined a group of patients who, over many years, 
required only on-demand transfusions, and had distinct clinical 
characteristics, indicating a milder phenotype, compared with 
those requiring scheduled transfusions. We also identified, 
beginning in the third decade of life, a striking shift in 
phenotype demonstrated by the development of intolerance to 
anaemia in patients aged 27–39 years, which has not been 
reported previously in haemoglobin E thalasssaemia. Our data 
show that splenectomy, while not associated with increased 
risk of death or a statistically significant increase in serious 
infections, did not eliminate the requirement for scheduled 
transfusions in most patients. Haemoglobin concentrations of 
4·5 g/dL or less, concentrations of serum ferritin exceeding 
1300 µg/L, and liver iron concentrations exceeding 5 mg/g dry 
weight of liver were found to be associated with poor survival. 
These thresholds of risks have not been previously defined in 
haemoglobin E thalassaemia; they differ from those previously 
calculated for thalassaemia major and thalassaemia intermedia 
not involving an allele for haemoglobin E.
Implications of all the available evidence
As the disease burden of thalassaemia continues to increase 
worldwide, resources for most of the world’s patients are scarce 
and fragmented, and survival is poor. Studies to generate 
evidence for the most cost-effective approach to management 
of haemoglobin E thalassaemia, the most common form of 
severe β-thalassaemia worldwide, are crucially needed. The 
implications of this study are important for haemoglobin E 
thalassaemia in Asia, where in many countries, children with this 
disease are placed on a lifetime of possibly unnecessary 
transfusion, on the basis of anaemia alone. To develop an 
evidence-based approach to transfusions in haemoglobin E 
thalassaemia, we propose that a controlled clinical trial should 
evaluate differing intensities of transfusion.
See Online for appendix
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polymorphism [G→A] in intron 2 of the BCL11A gene 
associated with increased fetal haemoglobin).11 We 
reviewed patient history and performed physical, height, 
and weight examinations and full blood counts up to 
three times a year, with a minimum of one examination 
per year. If patients did not return more frequently they 
were assessed only annually. Serum ferritin concentration 
was assessed every 6 months; serum thyroid stimulating 
hormone, fasting glucose, alanine aminotransferase, 
creatinine (and after 2011, calcium and phosphate) 
were measured annually. Abdominal ultrasound, and 
2D echocardiogram to estimate left ventricular ejection 
fraction and right atrial pressure, were performed 
annually after 2002. Liver iron concentrations were 
assessed over two periods, by chemical analysis of liver 
tissue obtained by percutaneous biopsy12 up to 2002, and 
through evaluation by FerriScan (Resonance Health, 
Burswood, WA, Australia)13 after 2009.
Before 1993 in Sri Lanka, most patients with 
haemoglobin E thalassaemia were not generally scheduled 
for blood transfusions. Instead, most were treated 
with on-demand transfusions during episodes of acute 
infection, before surgery, and during pregnancy. At the 
beginning of the study, we learned that, throughout 1993 
and 1994 in most patients, prescheduled regular blood 
transfusions had been initiated; in most patients, these 
had supported steady-state pretransfusion haemoglobin 
concentrations of approximately 6 g/dL. In many patients, 
transfusions had been administered in the absence of 
clear indications, and without provision of adequate iron-
chelation therapy, access to which was rare throughout the 
country before 1995. As a result, in several patients, there 
were indications, later confirmed by quantitation of liver 
iron concentrations, of iron burdens exceeding established 
thresholds of risk for premature death.14 Consequently, the 
first priorities in these patients were to reduce or 
discontinue transfusions and to intensify iron-chelation 
therapy, despite ongoing shortages of the infusion pumps 
required for deferoxamine infusions. After discussions 
with patients and the clinic paediatricians regarding 
potential risks and benefits, prescheduled transfusions 
were discontinued in 85 patients, because of uncertainty 
about indications, increasing concentrations of body iron, 
or both. Other patients continued to receive scheduled 
(regular [eight or more per year] or irregular [ fewer 
than eight per year] based on clinician discretion) 
transfusions. In patients with increasing spleen size, 
poor growth, failure to thrive, and other complications, 
attempts were made to maintain steady-state haemoglobin 
concentrations exceeding 8 g/dL. Further details are 
provided in the appendix (p 2).
Up to 2011, 73 patients underwent splenectomy, 
the indications for which were not consistently clear. 
Pneumococcal vaccination was administered before 
splenectomy. Daily folic acid was prescribed in all 
patients. Penicillin was prescribed in splenectomised 








Age at recruitment (years; 
n=109)
13 (8–21) 12 (7–19) 16 (8–36) 0·068*
Range 1–50 1–50 3–49 ··
Sex
Male 54/109 (50%) 32/77 (42%) 22/32 (69%) 0·012†
Female 55/109 (50%) 45/77 (58%) 10/32 (31%) ··
Ethnicity
Sinhalese 97/109 (89%) 67/77 (87%) 30/32 (94%) 0·50‡
Moors 12/109 (11%) 10/77 (13%) 2/32 (6%) ··
Employed or in education 73/94 (78%) 57/74 (77%) 16/20 (80%) 1·0‡
Married 38/95 (40%) 31/72 (43%) 7/23 (30%) 0·42†
Having living children 28/95 (29%) 22/72 (31%) 6/23 (26%) 0·88†
Genetic modifiers
Single gene deletional 
α-thalassaemia
7/109 (6%) 4/77 (5%) 3/32 (9%) 0·42‡
rs7482144 (Xmn1) 
polymorphism (G→A) 5ʹ 
to HBG2
14/109 (13%) 10/77 (13%) 4/32 (13%) 1·0‡
rs4671393 
polymorphism (G→A) in 
intron 2 of the BCL11A 
gene
30/105 (29%) 24/77 (31%) 6/28 (21%) 0·46†
Number of genetic 
modifiers
·· ·· ·· 0·88‡
0 63/105 (60%) 45/77 (58%) 18/28 (64%) ··
1 34/105 (32%) 26/77 (34%) 8/28 (29%) ··
2 8/105 (8%) 6/77 (8%) 2/28 (7%) ··
Splenectomy 73/109 (67%) 49/77 (64%) 24/32 (75%) 0·36†
Complications
Gallstones 53/100 (53%) 43/75 (57%) 10/25 (40%) 0·20†
Pulmonary artery 
pressure >30 mm Hg
35/88 (40%) 25/69 (36%) 10/19 (53%) 0·30†
Leg ulcers 35/103 (34%) 25/77 (32%) 10/26 (38%) 0·75†
Fractures 32/103 (31%) 24/77 (31%) 8/26 (31%) 1·0†
Ejection fraction <60% 31/101 (31%) 21/77 (27%) 10/24 (42%) 0·28†
Hypothyroidism 30/99 (30%) 22/77 (29%) 8/22 (36%) 0·66†
Delayed menarche 9/16 (56%) 9/14 (64%) 0/2 0·18‡
Short stature (less than 
the third percentile)
28/89 (31%) 24/73 (33%) 4/16 (25%) 0·77‡
Serious infections 20/99 (20%) 7/77 (9%) 13/22 (59%) <0·0001‡
Diabetes 13/106 (12%) 5/77 (6%) 8/29 (28%) 0·0062‡
Transfusion requirement§ 
(at end of follow-up or 
death)
·· ·· ·· 0·44†
Regular 32/109 (29%) 25/77 (32%) 7/32 (22%) ··
Irregular 22/109 (20%) 16/77 (21%) 6/32 (19%) ··
On demand 55/109 (50%) 36/77 (47%) 19/32 (59%) ··
Total number of 
transfusions given (n=107)
50·0 (27·5–94·5) 50·0 (22·5–90·0) 49·5 (30·0–94·2) 0·41*
Number of transfusions per 
year from birth (n=107)
1·6 (0·9–3·3) 1·6 (0·9–3·1) 1·8 (0·9–3·9) 0·92*
Number of transfusions per 
year from recruitment 
(n=107)
3·9 (1·8–7·6) 2·7 (1·6–5·2) 6·0 (3·8–9·5) 0·0022*
(Table 1 continues on next page)
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deferoxamine was irregular. After 2010, most patients 
who required chelation therapy were switched to orally 
active deferasirox.
All clinical decisions were taken in consultation with 
the Kurunegala Hospital’s (rotating) paediatricians.
Statistical analysis 
Descriptive statistics of patients were presented as 
numbers with percentages, or median with IQR. Non-
parametric analyses were performed for continuous data, 
and Pearson’s χ² test or Fisher’s exact test for categorical 
data. To calculate steady-state haemoglobin values, a 
summary statistic was calculated from all measure ments 
excluding those during acute infections or less than 
3 months following a blood transfusion. Survival analysis 
was done with right-censored data. Time to event was 
defined as the time between birth and death. Survival 
rates between groups were evaluated using Kaplan-Meier 
survival function estimate curves. Cox proportional 
hazards (CPH) models were used to identify risk factors 
of mortality. Stepwise variable selection procedure was 
adopted to identify risk factors of the multiple CPH 
models. Separate CPH models were fitted to identify 
the baseline characteristics, biochemical investigation, 
and complications that were associated with survival to 
control the confounding effects. Further, effects of the 
later two models were obtained with and without 
adjustment for the factors in the model with baseline 
characteristics. The effect of risk factors on mortality was 
presented with hazard ratios with 95% CIs. We evaluated 
the thresholds (cutoffs) beyond which patients showed 
poor survival. We serially assessed survival of patients for 
different thresholds of steady-state haemoglobin and 
liver iron and serum ferritin concentrations, and 
identified the levels associated with poor survival. 
Analyses were done with R version 3.6.6.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report.
Results 
Patients were recruited from Jan 1, 1997, to Dec 31, 2001, 
and followed up until Dec 31, 2017, for a median follow-up 
of 18 years (IQR 14–20). The original cohort included 
54 (50%) male patients and 55 (50%) female patients 
(appendix p 1).
Table 1 shows characteristics of the full cohort and in 
surviving and deceased patients. All patients had severe 
β-thalassaemia mutations.6 Genetic modifiers were 
identified in 42 (40%) of 105 patients (appendix p 3).
32 (29%) of 109 patients died during follow-up, of 
whom 22 (69%) were male. 77 (71%) patients were still 
alive as of 2017. Median survival was 49 years (95% CI 
45–not reached; figure). Compared with survivors, 
patients who died during the study period had a greater 
incidence of diabetes and of serious infections, many 
of which were fatal (table 1), including cholangitis, 
subdural empyema, pyogenic meningitis, schisto-
somiasis, skin abscesses, dental abscess (all in one 
patient each); meningoencephalitis (two patients); 
pneumonia (two patients); sepsis (two patients); and 
liver abscess (five patients). Deceased patients had 
received more transfusions per year from recruitment 
and had higher body iron burdens as estimated by 
serum ferritin concentration. Causes of death were 
infection (in 11 [34%] of 32 patients), heart failure 








(Continued from previous page)
Steady-state haemoglobin 
(g/dL; n=107) 
5·8 (5·2–6·6) 6·1 (5·3–6·9) 5·3 (4·0–6·1) 0·0015*
Haemoglobin F (%; n=20) 33·9 (30·5–44·7) 33·9 (30·5–44·7) NA ··
Most recent serum ferritin 
concentration (µg/L; n=105)
949 (603–1658) 854 (563–1259) 1377 (917–3100) 0·00080*
Range 33–9081 33–3395 334–9081 ··
>2500 µg/L 15/105 (14%) 5/76 (7%) 10/29 (34%) 0·00083‡
Most recent liver iron 
concentration (mg/g dry 
weight; n=103)
8·8 (4·7–13·4) 8·1 (4·1–12·7) 10·5 (6·7–14·6) 0·063*
Range 0·7–65·0 0·7–65·0 2·0–52·6 ··
>15 mg/g 16/103 (16%) 10/74 (14%) 6/29 (21%) 0·38‡
Age as of December, 2017, 
or at death (years; n=109)
30 (24–39) 31 (27–38) 27 (19–41) 0·11*
Data are median (IQR) or n/N (%), unless otherwise stated. The number available varies, in each case, because the data 
were either not available in the records or could not be provided by the patient. p values compare survivors versus 
non-survivors. NA=not available. *Mann-Whitney U test. †Pearson’s χ² test. ‡Fisher’s exact test. §Classified as regular 
(≥8 per year), irregular (<8 per year), or on demand.
Table 1: Patient demographic and clinical characteristics, stratified by outcome
Figure: Survival according to age in patients with haemoglobin E thalassaemia
Blue line is Kaplan-Meier survival function estimate curve with 95% confidence band. Censoring is indicated by 





















109 (0) 108 (2) 98 (12) 64 (17) 25 (23) 10 (29) 2 (32)
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and cancer (two [6%] patients). The cause of death was 
unknown in seven (22%) patients. Causes of death 
according to age are shown in the appendix (p 4).
Survival was poorer in male patients than in female 
patients (HR 2·51, 95% CI 1·16–5·43), and poorer in 
patients with elevated estimated body iron burdens as 
estimated by serum ferritin concentration than in 
patients without elevated serum ferritin concentration 
(adjusted HR 1·03, 1·01–1·06 per 100 units; table 2). 
Survival was better in patients who had presented late (ie, 
at older than younger ages) to medical attention. Survival 
was also better in those homozygous for the rs7482144 
(Xmn1) poly morphism 5ʹ to HBG2 than in those without 
this polymorphism (HR 0·27, 95% CI 0·08–0·92). 
Patients who were homozygous for the rs7482144 (Xmn1) 
poly morphism 5ʹ to HBG2 also had higher steady-state 
haemoglobin concentrations (6·4 g/dL, IQR 5·1–7·8) 
than those without this polymorphism (5·9 g/dL, 
5·2–6·4; p=0·029). Gallstones were associated with 
better survival (adjusted HR 0·28, 95% CI 0·10–0·74), 
and serious infections with poorer survival (adjusted 
HR 8·49, 2·90–24·84). Steady-state haemoglobin 
concen trations of 4·5 g/dL or lower (vs patients with 
concentration >4·5 g/dL; p=0·0036), and concentrations 
of serum ferritin exceeding 1300 µg/L (vs patients with 
concentration ≤1300 µg/L; p=0·015) and liver iron 
exceeding 5 mg/g dry weight of liver tissue (vs patients 
with concentration ≤5 mg/g; p=0·035) were associated 
with poorer survival (table 2, appendix p 5).
73 (67%) of 109 patients had a splenectomy. Median age 
at splenectomy was 11 years (IQR 8–19; range 2–50) 
years. Steady-state haemoglobin was lower, serum 
ferritin concentration higher, and diabetes and 
hypothyroidism more common, in patients who had 
splenectomy than in patients who did not (appendix p 6). 
Splenectomy was not associated with significant 
increases in the risks of death or serious infections 
(appendix p 6). Splenectomy did not eliminate a 
transfusion requirement in most patients: 42 (58%) of 73 
patients who had undergone a splenectomy returned to 
scheduled transfusions, following a median 7·5 years 
(IQR 4–14) of unscheduled (on-demand) transfusions 
only. It was unclear in many patients whether post-
splenectomy transfusion requirements were similar to 
those that had been recorded before splenectomy. 
Another 31 (43%) patients remained on unscheduled 
transfusions, a median 16 years (IQR 5–20) following 
splenectomy. Age at splenectomy did not differ 
significantly between patients who resumed (median age 
12 years, IQR 8–17), or did not resume (median age 
11 years, 8–21), scheduled transfusions (p=0·97). One in 
four evaluable patients who had splenectomy (17 [26%] of 
66) reported a history of serious infections; in most, the 
time between infection and splenectomy was not 
recorded. Awareness of serious infections altered 
referrals for splenectomy, and only one patient was 
referred after 2011. 24 (33%) of 73 patients who had a 
splenectomy died, a median 17 years (IQR 13–21; range 
10–57) following splenectomy; at the time of death, 
12 (50%) had been receiving scheduled transfusions. 
Causes of death, recorded in 19 (79%) patients, included 
infections (seven [29%] of 24 patients), heart failure 
(six [25%] patients), liver disease (four [17%] patients), 
and cancer (two [8%] patients).
Of 85 patients who discontinued prescheduled 
transfusions early in the study (ie, between 1997 and 
2001), 26 (31%) resumed regular transfusions at a median 
age of 18 years (IQR 12–26), after 7 years (5–13) of 
freedom from scheduled transfusions. Another 20 (24%) 
patients resumed irregular transfusions at a median age 
of 28 years (IQR 17–36), following 10 years (6–16) of 
freedom from scheduled transfusions. Transfusions 
were most commonly resumed because of worsening 
linear growth; other reasons included fatigue, headaches, 
exercise intolerance, chest pain, splenic enlargement, 
and the development of a leg ulcer. Two patients resumed 
after they developed extramedullary haematopoiesis 
and spinal cord compression; another resumed after 
developing severe bone pain related to undiagnosed 
hypo parathyroidism.
Hazard ratio p value
Baseline characteristics
Age at diagnosis (per additional year) 0·94 (0·90–0·98) 0·050
Male sex (vs female) 2·51 (1·16–5·43) 0·019
rs7482144 (Xmn1) polymorphism 
(G→A) 5ʹ to HBG2*
0·27 (0·08–0·92) 0·037
Biochemical investigations
Elevated steady-state haemoglobin 
(per additional unit)
0·78 (0·63–0·97) 0·026
Elevated mean serum ferritin 




Gallstones 0·19 (0·05–0·77) 0·020
Serious infections 11·50 (3·41–38·82) <0·0001
After adjustment for baseline characteristics
Biochemical investigations 
Elevated steady-state haemoglobin 
(per additional unit)
0·76 (0·55–1·05) 0·099*
Elevated mean serum ferritin 




Gallstones 0·28 (0·10–0·74) 0·010
Serious infections 8·49 (2·90–24·84) <0·0001
Baseline characteristics, biochemical investigations, and complications that are 
associated with the survival of patients with haemoglobin E thalassaemia. 
Biochemical investigations and complications have been evaluated with and 
without adjustment for significant baseline characteristics (ie, age, sex, and 
rs7482144 [Xmn1] polymorphism) of the patients. Normal serum ferritin 
concentration is 12–300 μg/L. Elevation over this represents iron overload, with 
various levels of risk. Normal haemoglobin concentration 13·5–17·5 g/dL for men, 
12·0–15·5 g/dL for women. *Versus patients without this polymorphism.
Table 2: Survival analysis of patients with haemoglobin E thalassaemia
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Survival in patients who, by the end of observation 
or death, were receiving no transfusions or on-demand 
transfusions (55 [50%] of 109 patients) did not differ 
significantly from that in those receiving scheduled 
transfusions (regular, 32 [29%] patients; irregular, 
22 [20%] patients; table 3, appendix p 7). Compared with 
patients receiving scheduled transfusions, patients 
receiving no or on-demand transfusions were older at 
diagnosis and had a higher prevalence of homozygosity 
for the Xmn1 polymorphism 5ʹ to HBG2, higher steady-
state haemoglobin concentrations, lower estimated iron 
burdens, and a lower prevalence of hypothyroidism, 
suggesting a milder pheno type.
No venous thromboembolic events were recorded. 
The number of complications was associated with the 
number of genetic modifiers: one or more complications 
developed in 48 (92%) of 52 patients with no 
genetic modifiers, in 21 (81%) of 26 patients with 
one genetic modifier, and in all four (100%) patients 
with two genetic modifiers (p=0·41). Complications 
in the oldest surviving patients are detailed in the 
appendix (p 8).
In patients with evaluable growth records, final adult 
height exceeding the third percentile was achieved in 
61 (69%) of 89 patients and mid-parental height was 
achieved in 40 (52%) of 77 patients. Median age at 
menarche, available in 49 (89%) of 55 women who had 
achieved puberty spontaneously, was 16 years (IQR 14–17), 
significantly older than the age at menarche of their 
mothers (14 years [13–15] years; p=0·002), available in 
16 (29%) of 55 mother-daughter pairs. Tanner staging 
was not systematically recorded in most male patients.
In 20 patients aged 27–39 years, we observed a striking 
development of intolerance to anaemia (presenting as 
fatigue, exercise intolerance, or chest pain) following 
years of normal activities in the absence of scheduled 
transfusions (appendix p 9), unrelated to hypersplenism 
or accelerated red cell haemolysis. Scheduled trans-
fusions were initiated or resumed in these patients.
Discussion 
To our knowledge, this is the first longitudinal analysis of 
survival, and factors influencing survival, in people with 
haemoglobin E thalassaemia, the most common form of 
severe β-thalassaemia worldwide. Survival in patients 
with haemoglobin E thalassaemia was shorter than 
that in people with other forms of thalassaemia15,16 or 
in individuals without thalassaemia in Sri Lanka17 
(cumulative survival by age 50 years was estimated as 
93·4% in a large cohort of patients with thalassaemia 
intermedia;16 life expectancy in Sri Lanka at birth is 
estimated at 76·98 years).17 Deaths and clinical compli-
cations were related to both chronic anaemia 
and iron overload. Some findings were unexpected and 
remain unexplained. Gallstones were associated with 
better survival. Venous thromboembolism was not 
observed in any patients in the study cohort, by contrast 
with findings in other studies.18,19 Another unanticipated 
finding was the striking subacute development of 
intolerance to anaemia in older patients (aged 27–39 years) 
who had previously thrived without regular transfusions, 
consistent with our previous studies of age-related 
changes in adaptation to severe anaemia,20 and similar to 
findings of a previous study of older patients with 
thalassaemia intermedia not involving haemoglobin E, all 
of whom had been started on scheduled transfusions 
after age 18 years, and were in a similar age range to 
our patients.21 We hypothesise that this finding might be 
related to changes in responsiveness to erythropoietin 
with age, as previously observed;20 measurements of 
serum erythro poietin are awaited to provide secure con-
clusions. Further findings will be published subsequently. 
Prospective studies could evaluate factors important in 
these changes in phenotype.
This is also the first study, to our knowledge, to 
report thresholds of risk of iron overload in haemo-
globin E thalassaemia, potentially offering guidance for 
No transfusion or 
on-demand 
transfusion (n=55)
Regular or irregular 
transfusion (n=54)
p value 
Age at diagnosis (years) 8 (4–18) 3 (1–7) <0·0001*
Age at present or death (years) 31 (26–42) 30 (22–36) 0·21*
Sex
Male 34/55 (62%) 20/57 (35%) 0·017†
Female 21/55 (38%) 37/57 (65%) ··
α-thalassaemia 6/55 (11%) 1/54 (2%) 0·11‡
rs7482144 (Xmn1) polymorphism 
(G→A) 5ʹ to HBG2
11/55 (20%) 3/54 (6%) 0·042‡
rs4671393 polymorphism (G→A) in 
intron 2 of the BCL11A gene
20/52 (38%) 10/53 (19%) 0·045†
Splenectomy 31/55 (56%) 42/54 (78%) 0·030†
Steady-state haemoglobin (g/dL) 6·2 (5·8–7·0) 5·4 (4·9–6·0) <0·0001*
Most recent serum ferritin 
measurement (µg/L)
787 (480–1157) 1255 (811–2042) 0·0012*
Liver iron concentration (mg/g dry 
weight)
6·8 (3·4–12·4) 10·5 (5·9–14·2) 0·029*
Complications
Gall stones 25/47 (53%) 28/53 (53%) 1·0†
Pulmonary artery pressure >30 mm 
Hg
13/40 (33%) 22/48 (46%) 0·29†
Leg ulcers 18/51 (35%) 17/52 (33%) 0·94†
Fractures 16/51 (31%) 16/52 (31%) 1·0†
Ejection fraction <60% 16/51 (31%) 15/50 (30%) 1·0†
Hypothyroidism 8/45 (18%) 22/54 (41%) 0·016†
Delayed menarche 11/42 (26%) 17/47 (36%) 0·43†
Short stature (less than the third 
percentile)
4/5 (80%) 5/11 (45%) 0·45†
Serious infections 8/48 (17%) 12/51 (24%) 0·55†
Diabetes 4/52 (8%) 9/54 (17%) 0·24‡
Death 19/55 (35%) 13/54 (24%) 0·32†
Data are median (IQR) or n/N (%). *Mann-Whitney U test. †Pearson’s χ² test. ‡Fisher’s exact test.
Table 3: Clinical characteristics and complications, stratified by transfusion group
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management. The threshold of serum ferritin (1300 μg/L) 
associated with poorer survival was lower than that in 
thalassaemia major (2500 μg/L22), but higher than that in 
thalassaemia intermedia not involving haemoglobin E 
(800 μg/L).23 The threshold of liver iron concentration 
associated with poorer survival (5 mg/g) was lower than 
that in thalassaemia major (15 mg/g)14 and similar to that 
in thalassaemia intermedia not involving haemoglobin E.24
Two-thirds of patients underwent splenectomy. By 
contrast with previous findings,25 in over half of these 
patients, splenectomy did not permanently mitigate the 
requirement for prescheduled transfusions. Although 
it might seem prudent to recommend avoidance of 
splenectomy in patients with haemoglobin E thalassaemia, 
shortages of blood throughout Asia complicate disease 
management,2 such that steady-state haemoglobin 
concentrations sufficient to suppress splenic expansion 
are often not achieved.26
Regarding the fundamental question of which 
patients with haemoglobin E thalassaemia should have 
transfusions and on what regimens, our findings could 
guide future work. Judicious withdrawal of transfusions 
in this study permitted identification of approximately 
50% of patients who were able to continue on-demand 
transfusions. Compared with patients requiring regu-
larly scheduled transfusions, these patients appeared to 
have a milder phenotype, as suggested by several factors 
including a clinically modest but statistically significant 
higher mean steady-state haemoglobin concentration, 
consistent with our previous findings.6 However, even 
in patients with this mild phenotype, the safety of on-
demand transfusions might be questioned because 
of the high prevalence of complications that emerged 
in this study. Although maintenance of steady-state 
haemoglobin concentrations of 4·5 g/dL (the threshold 
for survival identified for haemoglobin E thalassaemia 
in this study) is not recommended, uncertainty persists 
as to the optimal target haemoglobin concentration, and 
by extension intensity of transfusions, in this disorder. 
In several countries, many affected children begin 
prescheduled transfusions at diagnosis; one study 
reported the primary, and arbitrary, indication for this 
approach was the country of birth.27 Furthermore, 
traditional guidelines for transfusions in thalassaemia 
that propose maintenance of steady-state haemoglobin 
concentrations of 9·5–10·0 g/dL arise from one 
small retrospective study in European patients with 
thalassaemia major.28 Whether such a regimen is appro-
priate in all patients with haemoglobin E thalassaemia, 
many of whom might adapt better to anaemia related to 
the decreased oxygen affinity of haemoglobin E29 and 
who, even when irregularly transfused, have better 
survival than those with thalassaemia major,8,9 remains 
unclear.
Our study has limitations. During the 20-year period, 
approaches to management shifted, complicating some 
evaluations. There is little information on deaths, and 
no post-mortem data. Quantitative measurements of 
body iron burden were were not regularly assessed, 
because of resource constraints. Baseline haemoglobin F 
concentrations were not assessed in most patients. 
Resting ejection fractions provide little information 
about cardiac reserve or iron loading. Haemoglobin and 
serum ferritin concentrations changed over the life 
course of patients; although we considered haemoglobin 
and recent ferritin concentrations, time-dependent 
analysis could be considered in future. Another 
limitation was that, before the study, transfusions had 
been started in many patients without adequate iron-
chelation therapy; it, therefore, became the priority to 
reduce, where possible, transfusions in patients with 
iron burdens associated with increased risk of death. 
Access to chelation therapy continued to be problematic, 
limiting transfusion approaches in many patients.
Throughout Asia where the burden of thalassaemia 
is increasing,30 most resources for its management 
continue to be scarce.2,4 Programmes to reduce the 
incidence of thalassaemia in neonates, which are 
ongoing in several countries,2 have not yet had a 
substantial impact in Sri Lanka, possibly related to 
challenges in coordination.9 In parallel, although cures 
are offered to patients in higher-income countries,31 
resources for most of the world’s patients are 
fragmented, and survival remains poor.2,32 Indeed, 
survival of patients with haemoglobin E thalassaemia in 
other Asian countries, which lack the publicly financed, 
freely delivered health-care system of Sri Lanka,33 is 
likely to be poorer than that reported in this study. 
Particularly in countries with ongoing blood shortages, 
controlled clinical trials to evaluate the benefits and 
risks of different transfusion regimens, in parallel with 
evaluation of drugs to increase fetal haemoglobin34 or 
total haemoglobin,35 are crucially needed to address 
these fundamental questions in this under-studied 
disease.
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